IndustryCompany release

NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path

🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026

The Nasdaq-listed company has booked a Type B End-of-Phase meeting to discuss accelerated approval for intranasal NEO100 in brain cancer, as its CEO added to his share purchases.

NeOnc Technologies (Nasdaq: NTHI) said on 16 November 2026 that it has a Type B End-of-Phase meeting with the US Food and Drug Administration scheduled for early January 2027. The agenda covers a possible accelerated approval pathway for NEO100, an intranasal treatment for brain cancer, and the design of a Phase 3 confirmatory trial.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗

Article written by VigiEye from the official source (Neonc Technologies Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →